Launch of Lexapro commenced in Japan
* Clinical phase III studies in Japan have confirmed the positive efficacy and
tolerability profile of Lexapro(®)
* Lexapro(®) in Japan will contribute to Lundbeck's financial performance from
2012
H. Lundbeck A/S today announced that its partners Mochida Pharmaceutical Co.,
Ltd. (Mochida) and Mitsubishi Tanabe Pharma Corporation (MTPC) have launched
Lexapro(®) 10mg (escitalopram) in Japan, for which Mochida obtained the
marketing approval following the NHI (National Health Insurance) Drug Price
listing.
"It is a milestone in our global expansion strategy that Lexapro(®) is now
available in Japan following a fast regulatory process," says Lundbeck Senior
Vice President Ole Chrintz, International Markets. He continues: "We are pleased
that Lexapro(®) will now also contribute to improving quality of life for
patients in Japan diagnosed with depression."
Lexapro(®) has been very well-received by the patients and doctors for the
treatment of depression in many countries, and is currently the most prescribed
branded anti-depressant in the World.
Mochida and MTPC estimate sales of Lexapro(®) amounting to JPY 3 billion (DKK
~0.2 billion) for the first year following the launch and JPY 33.8 billion (DKK
~2.3 billion) in its peak year 6 years later.
For reference:
Brand Name: Lexapro(®) 10mg
Ingredients and Contents: 12.77mg escitalopram oxalate per tablet (10mg
escitalopram per tablet)
Indication: Depression and depressive symptoms
Dosage and Administration: Usually, to adults, 10mg of escitalopram is orally
administered once daily after meal in the evening. The dosage may be adjusted
according to the patient's age and symptoms; however, the daily dose should not
be increased over 20mg.
Package: 28,100,140,500 tablets (PTP), 500 tablets (Bottle)
NHI Drug Price: JPY 212.00 per tablet
Date of Approval: April 22, 2011
* Lexapro(®) - the most prescribed branded antidepressant in the world - now
also available to Japanese patients
* Clinical phase III studies in Japan have confirmed the positive efficacy and
tolerability profile of Lexapro(®)
* Lexapro(®) in Japan will contribute to Lundbeck's financial performance from
2012
H. Lundbeck A/S today announced that its partners Mochida Pharmaceutical Co.,
Ltd. (Mochida) and Mitsubishi Tanabe Pharma Corporation (MTPC) have launched
Lexapro(®) 10mg (escitalopram) in Japan, for which Mochida obtained the
marketing approval following the NHI (National Health Insurance) Drug Price
listing.
"It is a milestone in our global expansion strategy that Lexapro(®) is now
available in Japan following a fast regulatory process," says Lundbeck Senior
Vice President Ole Chrintz, International Markets. He continues: "We are pleased
that Lexapro(®) will now also contribute to improving quality of life for
patients in Japan diagnosed with depression."
Lexapro(®) has been very well-received by the patients and doctors for the
treatment of depression in many countries, and is currently the most prescribed
branded anti-depressant in the World.
Mochida and MTPC estimate sales of Lexapro(®) amounting to JPY 3 billion (DKK
~0.2 billion) for the first year following the launch and JPY 33.8 billion (DKK
~2.3 billion) in its peak year 6 years later.
For reference:
Brand Name: Lexapro(®) 10mg
Generic name: Escitalopram oxalate
Ingredients and Contents: 12.77mg escitalopram oxalate per tablet (10mg
escitalopram per tablet)
Indication: Depression and depressive symptoms
Dosage and Administration: Usually, to adults, 10mg of escitalopram is orally
administered once daily after meal in the evening. The dosage may be adjusted
according to the patient's age and symptoms; however, the daily dose should not
be increased over 20mg.
Package: 28,100,140,500 tablets (PTP), 500 tablets (Bottle)
NHI Drug Price: JPY 212.00 per tablet
Date of Approval: April 22, 2011
No comments:
Post a Comment
Note: only a member of this blog may post a comment.